Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (canceled)

Claim 2. (canceled)

Claim 3. (previously presented) An isolated peptide or a salt thereof, wherein the peptide has the following formula (I):



(I)

Claim 4. (canceled)

Claim 5. (previously presented) An isolated peptide or a salt thereof, wherein the peptide has the following formula (II):



(II)

Claim 6. (canceled)

Claim 7. (canceled)

Claim 8. (canceled)

Claim 9. (canceled)

Claim 10. (previously presented) An isolated lower-alkylated derivative of a peptide or a salt thereof, wherein said derivative has the following formula (VI):



(VI)

, wherein R is a methyl group.

Claim 11. (canceled)

Claim 12. (canceled)

Claim 13. (previously presented) An isolated peptide or a salt thereof, wherein the peptide has the following formula (IV):



(IV)

Claim 14. (canceled)

Claim 15. (canceled)

Claim 16. (previously presented) An isolated peptide or a salt thereof, wherein the peptide has the following formula (V):



(V)

Claims 17 to 23. (canceled)

Claim 24. (previously presented) The peptide according to claim 3, wherein the peptide is isolated and purified from a culture of Pseudomonas sp. RtIB026 deposited under accession number FERM BP-7436.

Claim 25. (previously presented) A method of preparing the peptide according to claim 3, comprising:

culturing Pseudomonas sp. RtIB026 deposited under accession number FERM BP-7436,

obtaining a culture product of the microorganism; and

recovering the peptide according to claim 3 from the culture product.

Claim 26. (currently amended) An antiviral composition having antiviral activity against infectious hematopoietic necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels, rhabdovirus (EVEX) in European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV), the composition comprising a pharmaceutically effective amount of the peptide according to claim 3, in combination with a pharmaceutically acceptable carrier.

Claim 27. (currently amended) A method of preventing a subject from infection with a virus and/or treating a subject

suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 3 as an effective ingredient, wherein the infection with a virus is an infection with at least one virus selected from the group consisting of infectious hematopoietic necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels, rhabdovirus (EVEX) in European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV).

Claim 28. (previously presented) The peptide according to claim 13, wherein the peptide is isolated and purified from a culture of Pseudomonas sp. RtIB026 deposited under accession number FERM BP-7436.

Claim 29. (previously presented) A method of preparing the peptide according to claim 13, comprising:

culturing Pseudomonas sp. RtIB026 deposited under accession number FERM BP-7436,

obtaining a culture product of the microorganism; and

recovering the peptide according to claim 13 from the culture product.

Claim 30. (currently amended) An antiviral composition having antiviral activity against infectious hematopoietic necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels; rhabdovirus (EVEX) in European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV), the composition comprising a pharmaceutically effective amount of the peptide according to claim 13, in combination with a pharmaceutically acceptable carrier.

Claim 31. (currently amended) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 13 as an effective ingredient, wherein the infection with a virus is an infection with at least one virus selected from the group consisting of

infectious hematopoietic necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels, rhabdovirus (EVEX) in European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV).

Claim 32. (previously presented) The peptide according to claim 16, wherein the peptide is isolated and purified from a culture of Pseudomonas sp. RtIB026 deposited under accession number FERM BP-7436.

Claim 33. (previously presented) A method of preparing the peptide according to claim 16, comprising:

culturing Pseudomonas sp. RtIB026 deposited under accession number FERM BP-7436,

obtaining a culture product of the microorganism; and

recovering the peptide according to claim 16 from the culture product.

Claim 34. (currently amended) An antiviral composition having antiviral activity against infectious hematopoietic

necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels, rhabdovirus (EVEX) in European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV), the composition comprising a pharmaceutically effective amount of the peptide according to claim 16, in combination with a pharmaceutically acceptable carrier.

Claim 35. (currently amended) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 16 as an effective ingredient, wherein the infection with a virus is an infection with at least one virus selected from the group consisting of infectious hematopoietic necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels, rhabdovirus (EVEX) in European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV).

Claim 36. (currently amended) An antiviral composition having antiviral activity against infectious hematopoietic necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels, rhabdovirus (EVEX) in European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV), the composition comprising a pharmaceutically effective amount of the peptide according to claim 5, in combination with a pharmaceutically acceptable carrier.

Claim 37. (currently amended) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 5 as an effective ingredient, wherein the infection with a virus is an infection with at least one virus selected from the group consisting of infectious hematopoietic necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels, rhabdovirus (EVEX) in

European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV).

Claim 38. (canceled)

Claim 39. (canceled)

Claim 40. (currently amended) An antiviral composition having antiviral activity against infectious hematopoietic necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels, rhabdovirus (EVEX) in European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV), the composition comprising a pharmaceutically effective amount of the peptide according to claim 10, in combination with a pharmaceutically acceptable carrier.

Claim 41. (currently amended) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective

amount of the peptide according to claim 10 as an effective ingredient, wherein the infection with a virus is an infection with at least one virus selected from the group consisting of infectious hematopoietic necrosis virus (IHNV) in salmonid, rhabdovirus (EVA) in American eels, rhabdovirus (EVEX) in European eels, swine influenza virus, avian influenza virus, swine herpes virus, swine Japanese encephalitis virus, shrimp virus (white spot syndrome virus) and hepatitis C virus (HCV).